A biocompatible and fully erodible conducting polymer enables implanted rechargeable Zn batteries
Jia X., Ma X., Zhao L., Xin M., Hao Y., Sun P.
Animal Study, published in Chem Sci (2023) — summary generated from the PubMed abstract.
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
- Level A · Stronger Clinical Evidence
- Level B · Emerging clinical evidence with positive signals
- Level C · Early human research exploring benefits
- Level D · Scientific groundwork from lab and animal studies
- Emerging · Emerging topic under active research
This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.
- Study type
- Animal Study
- Journal
- Chem Sci (2023)
- Reported sample size
- —
- Source database
- Europe PMC
- PMID
- 36845924
- PMCID
- PMC9944696
- DOI
- 10.1039/d2sc06342e
- Citations
- 11
Abstract (original English)
Implanted rechargeable batteries that can provide energy over a sufficient lifetime and ultimately degrade into non-toxic byproducts are highly desirable. However, their advancement is significantly impeded by the limited toolbox of electrode materials with a known biodegradation profile and high cycling stability. Here we report biocompatible, erodible poly(3,4-ethylenedioxythiophene) (PEDOT) grafted with hydrolyzable carboxylic acid pendants. This molecular arrangement combines the pseudocapacitive charge storage from the conjugated backbones and dissolution via hydrolyzable side chains. It demonstrates complete erosion under aqueous conditions in a pH-dependent manner with a predetermined lifetime. The compact rechargeable Zn battery with a gel electrolyte offers a specific capacity of 31.8 mA h g -1 (57% of theoretical capacity) and outstanding cycling stability (78% capacity retention over 4000 cycles at 0.5 A g -1 ). Subcutaneous implantation of this Zn battery into Sprague-Dawley (SD) rats demonstrates complete biodegradation in vivo and biocompatibility. This molecular engineering strategy presents a viable avenue for developing implantable conducting polymers with a predetermined degradation profile and high energy storage capability.
What this study does not prove
- • This study does not prove SVF is an approved treatment or a replacement for standard care.
- • This is preclinical work; animal or laboratory results cannot be applied to humans.
Evidence level
Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.
How we grade evidenceBrowse all related research
Filter the research library by this study's title keywords, author, or publication year.